Key result
PCOS is linked to ~16% higher serum sphingolipids, driven by elevated sphingosine-1-phosphate, ceramide, and sphingomyelin.
Why the study?
The roles of sphingolipids in polycystic ovary syndrome (PCOS) remain unknown.
Do serum sphingolipid profiles differ between women with different subtypes of PCOS and healthy controls?
Case-Control (n=144)
No
Do serum sphingolipid profiles differ between women with different subtypes of PCOS and healthy controls?
Effect estimate: 15.9% increase
p-value: p=<0.05
Serum sphingolipids, particularly SM species with long saturated acyl chains and LacCer, show potential as diagnostic biomarkers for different subtypes of PCOS.
Sphingolipid elevations may support biomarker exploration across PCOS subtypes; hypothesis-generating and requires prospective validation before clinical use.
The roles of sphingolipids in polycystic ovary syndrome (PCOS) are still unknown. This study aimed to investigate the sphingolipid characteristics for different types of PCOS using liquid chromatography-mass spectrometry (LC-MS). A total of 107 women with PCOS and 37 healthy women as normal controls were studied. PCOS patients were further classified into non-obesity with insulin resistance (IR) (NOIR), obesity with IR (OIR), and non-obesity and non-IR (NIR) subgroups. A total of 87 serum sphingolipids, including 9 sphingosines, 3 sphinganines, 1 sphingosine-1-phosphate (S1P), 19 ceramides (Cers), 1 ceramide-1-phosphate, 44 sphingomyelins (SMs), 4 hexosylceramides, and 6 lactosylceramides (LacCers) were analyzed using an improved sphingolipidomic approach based on LC-MS. Notable elevations in the levels of S1P, Cer, and SM were observed in PCOS patients when compared with healthy women, and SM species with long saturated acyl chains showed potential as novel biomarkers of PCOS. In addition, the level of LacCer was only elevated in NIR, and there was almost no change in NOIR and OIR. This study is the first to report the comprehensive sphingolipidomic profiling of different subgroups of PCOS with or without IR or obesity and suggests that serum sphingolipids might be useful as diagnostic biomarkers for different types of PCOS.
No takes yet. Share an insight, caveat, or question.
Li et al. (2019) conducted a case-control in Polycystic Ovary Syndrome (n=144). Polycystic Ovary Syndrome vs. Healthy women was evaluated on Total serum sphingolipid content (15.9% increase, p=<0.05). Polycystic ovary syndrome was associated with a 15.9% increase in total serum sphingolipid content compared to healthy women, driven by elevations in sphingosine-1-phosphate, ceramide, and sphingomyelin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: